This Gentex Analyst Turns Bearish; Here Are Top 5 Downgrades For Tuesday
Analysts downgraded Gentex, Personalis, Goosehead Insurance, cutting ratings and several price targets.
Stocks · News reference
Gentex Affirms FY2026 Sales Guidance of $2.650B-$2.750B vs $2.692B Est
Gentex (NASDAQ:GNTX) affirms FY2026 sales outlook from $2.650 billion-$2.750 billion to $2.650 billion-$2.750 billion vs $2.692 billion estimate.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Goldman Sachs Downgrades Gentex to Sell, Lowers Price Target to $20
Goldman Sachs analyst Mark Delaney downgrades Gentex (NASDAQ:GNTX) from Neutral to Sell and lowers the price target from $23 to $20.
Gentex Announces Third Quarter 2026 Cash Dividend
Gentex Corporation announced a quarterly cash dividend of $0.12 per share payable on October 21, 2026, to shareholders of record as of October 7, 2026. The company is a leading supplier of digital vision, connected car, dimmable glass, fire protection technologies, medical devices, and consumer electronics.
JP Morgan Maintains Neutral on Gentex, Lowers Price Target to $27
JP Morgan analyst Rajat Gupta maintains Gentex (NASDAQ:GNTX) with a Neutral and lowers the price target from $28 to $27.